Amgen loses battle with Colorado over prescription drug affordability board
In a blow to the pharmaceutical trade, a U.S. courtroom decide dominated {that a} Colorado state board can proceed with plans to put limits on the costs paid for medicines, the primary such resolution to assist the controversial makes an attempt by some states to manage their prescription drug spending.
The case had been filed final yr by Amgen after the state Prescription Drug Affordability Board decided that its big-selling remedy known as Enbrel is unaffordable and started a course of to create a so-called higher fee restrict. This is able to set up a fee ceiling for residents who’re coated by a authorities company or a business well being plan.
Amgen, nevertheless, argued that the board is unconstitutional as a result of its actions battle with federal regulation and would regulate enterprise exterior of Colorado, amongst different points. The corporate additional contended that the board desires to “impose arbitrary value controls” on the sale of medication — an argument taken up by the pharmaceutical trade, at giant — and would additionally “strip away” mental property rights.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
